101. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
- Author
-
Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, and Protzer U
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Cell Survival, Coculture Techniques, Dendritic Cells immunology, Female, Glypicans genetics, Glypicans immunology, HLA-A2 Antigen genetics, HLA-A2 Antigen immunology, Hep G2 Cells, Humans, Immunodominant Epitopes, Interferon-gamma immunology, Interferon-gamma metabolism, Liver Neoplasms genetics, Liver Neoplasms immunology, Liver Neoplasms metabolism, Liver Neoplasms pathology, Mice, SCID, Time Factors, Transfection, Xenograft Model Antitumor Assays, CD8-Positive T-Lymphocytes transplantation, Carcinoma, Hepatocellular therapy, Cytotoxicity, Immunologic, Dendritic Cells metabolism, Genes, T-Cell Receptor, Genetic Engineering methods, Glypicans metabolism, HLA-A2 Antigen metabolism, Immunotherapy, Adoptive methods, Liver Neoplasms therapy, Lymphocyte Activation
- Abstract
Background & Aims: Cancer therapies are being developed based on our ability to direct T cells against tumor antigens. Glypican-3 (GPC3) is expressed by 75% of all hepatocellular carcinomas (HCC), but not in healthy liver tissue or other organs. We aimed to generate T cells with GPC3-specific receptors that recognize HCC and used them to eliminate GPC3-expressing xenograft tumors grown from human HCC cells in mice., Methods: We used mass spectrometry to obtain a comprehensive peptidome from GPC3-expressing hepatoma cells after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to identify immunodominant peptides. To circumvent GPC3 tolerance resulting from fetal expression, dendritic cells from HLA-A2-negative donors were cotransfected with GPC3 and HLA-A2 RNA to stimulate and expand antigen-specific T cells., Results: Peptide GPC3367 was identified as a predominant peptide on HLA-A2. We used A2-GPC3367 multimers to detect, select for, and clone GPC3-specific T cells. These clones bound the A2-GPC3367 multimer and secreted interferon-γ when cultured with GPC3367, but not with control peptide-loaded cells. By genomic sequencing of these T-cell clones, we identified a gene encoding a dominant T-cell receptor. The gene was cloned and the sequence was codon optimized and expressed from a retroviral vector. Primary CD8(+) T cells that expressed the transgenic T-cell receptor specifically bound GPC3367 on HLA-A2. These T cells killed GPC3-expressing hepatoma cells in culture and slowed growth of HCC xenograft tumors in mice., Conclusions: We identified a GPC3367-specific T-cell receptor. Expression of this receptor by T cells allows them to recognize and kill GPC3-positive hepatoma cells. This finding could be used to advance development of adoptive T-cell therapy for HCC., (Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF